Thursday, February 13, 2014
This week in
Publication and contact
signal transducer (IL-6ST;
kinase (JAK); signal
transducer and activator of transcription 3 (STAT3)
In vitro studies suggest two marketed drugs could inform the
design of inhibitors that block the IL-6-CD130 interaction and help treat
cancer. Fragment-based drug design and virtual screening identified raloxifene
as potential inhibitors of the IL-6-CD130 interaction that activates JAK and
STAT3 signaling. In a CD130+ human
pancreatic cancer cell line, both drugs reduced viability at micromolar IC50
values. In an estrogen
receptor-negative human breast cancer cell line, the drugs
reduced viability at micromolar IC50 values. Ongoing work includes
optimizing the two drugs for potency against the IL-6-CD130 interaction.
Eli Lilly and Co. and Takeda
Pharmaceutical Co. Ltd. market Evista
raloxifene, a selective estrogen receptor modulator (SERM), to treat
osteoporosis and breast cancer.
Pharmaceuticals Inc. and Pfizer
Inc. market the SERM Conbriza
bazedoxifene to treat osteoporosis.
Published online Feb. 13, 2014
available for partnering
Li, H. et al. J. Med.
published online Jan. 23, 2014;
Contact: Chenglong Li, The Ohio State University, Columbus, Ohio
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]